- Home
- XPO vs INCY Comparison
XPO vs INCY Comparison
Compare XPO & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPO
- INCY
- Stock Information
- Founded
- XPO 2000
- INCY 1991
- Country
- XPO United States
- INCY United States
- Employees
- XPO N/A
- INCY N/A
- Industry
- XPO Transportation Services
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- XPO Consumer Discretionary
- INCY Health Care
- Exchange
- XPO Nasdaq
- INCY Nasdaq
- Market Cap
- XPO 15.3B
- INCY 13.0B
- IPO Year
- XPO N/A
- INCY 1993
- Fundamental
- Price
- XPO $138.30
- INCY $70.20
- Analyst Decision
- XPO Strong Buy
- INCY Hold
- Analyst Count
- XPO 17
- INCY 20
- Target Price
- XPO $141.35
- INCY $72.75
- AVG Volume (30 Days)
- XPO 1.1M
- INCY 1.5M
- Earning Date
- XPO 07-31-2025
- INCY 07-29-2025
- Dividend Yield
- XPO N/A
- INCY N/A
- EPS Growth
- XPO 60.50
- INCY N/A
- EPS
- XPO 3.25
- INCY 0.10
- Revenue
- XPO $8,008,000,000.00
- INCY $4,413,226,000.00
- Revenue This Year
- XPO $0.62
- INCY $13.48
- Revenue Next Year
- XPO $4.15
- INCY $10.37
- P/E Ratio
- XPO $41.75
- INCY $723.63
- Revenue Growth
- XPO 1.95
- INCY 17.13
- 52 Week Low
- XPO $85.06
- INCY $53.56
- 52 Week High
- XPO $161.00
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- XPO 68.12
- INCY 55.91
- Support Level
- XPO $128.36
- INCY $67.17
- Resistance Level
- XPO $134.00
- INCY $71.29
- Average True Range (ATR)
- XPO 3.83
- INCY 1.51
- MACD
- XPO 0.26
- INCY 0.06
- Stochastic Oscillator
- XPO 82.25
- INCY 74.23
About XPO XPO Inc.
Following the spinoff of its contract logistics division (GXO) in 2021 and freight brokerage operations (RXO) in 2022, XPO is moving closer to becoming a pure-play asset-based less-than-truckload carrier. We estimate LTL shipping makes up 60% of total revenue, with XPO's European truckload and LTL operations making up 40%. However, XPO's LTL segment EBITDA mix is much higher than 60%. We believe XPO intends to divest its European trucking division once it finds the right buyer.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.